Hyperphosphatemia is a medical condition which
involves increased level of serum phosphate concentration in the blood.
Phosphate is required for bone and cell formation, genetic coding and energy
metabolism.
Access
More About This Research at:
An
individual is said to have hyperphosphatemia, if the phosphate concentration
increasing beyond > 4.5 mg/dL (> 1.46 mmol/L). Similar to calcium, vitamin D is required to
properly absorb phosphate. The various causes of hyperphosphatemia include
excessive intake of phosphate, inadequate excretion of phosphates,
hypothyroidism, high vitamin D levels, and injuries causing muscle damage.
Request
to Get the Sample Pages at:
Signs and
symptoms associated with the hyperphosphatemia include renal osteodystrophy,
secondary hyperparathyroidism and ectopic calcification. Hyperphosphatemia can
be treated with phosphate binders, vitamin D analogs, and dietary restriction
of phosphate.
Chugai
Pharmaceutical Co. Ltd. is developing EOS789 as an oral formulation for the
treatment of hyperphosphatemia. Some of the other companies developing
hyperphosphatemia therapeutics include Ardelyx Inc., and OPKO Health Inc.
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with the detailed analysis
of pipeline and clinical trials.
Pipeline
analysis of drugs by phases includes product description and development
activities including information about clinical results, designations,
collaborations, licensing, grants, technology, and others.
No comments:
Post a Comment